BioMarin's Cancer Drug Purchased by Medivation for $410 Million Upfront

Biotech Investing

BioMarin Pharmaceutical’s (NASDAQ:BMRN) potential cancer drug talazoparib is to be purchased by Medivation (NASDAQ:MDVN) in a deal valued at $400 million.

BioMarin Pharmaceutical’s (NASDAQ:BMRN) potential cancer drug talazoparib is to be purchased by Medivation (NASDAQ:MDVN) in a deal valued at $570 million.
According to the press release:

Medivation, Inc. (Nasdaq:MDVN) and BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that they have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis.
[…] Under the terms of the agreement, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory and sales-based milestones and mid-single digit royalties for talazoparib. At the closing of the transaction, Medivation will assume all financial obligations associated with the development and commercialization of talazoparib.

Click here to read the full press release from BioMarin Pharmaceutical and Medivation.

The Conversation (0)
×